S4 Ep19: Not So Different: Gary Lyman, MD Details What Needs to Be Done to Ensure Physician Confidence in Biosimilars - a podcast by Not So Different: a Podcast from The Center for Biosimilars

A major barrier to biosimilar adoption is physician hesitancy when it comes to prescribing these agents, especially in the oncology space. Physicians often want more clinical or real-world evidence on the safety and efficacy of biosimilars compared with reference products in patients with cancer, for whom the stakes are high when choosing a therapeutic or supportive agent. Additionally, some clinicians worry about having to stock multiple biosimilars for a single reference product. These may require different storage conditions and increase the risk of administering the wrong agent, creating financial risk for the practice.
We sat down with Gary Lyman, MD, MPH, an oncologist, hematologist, public health researcher, and long-time biosimilar advocate who has also helped develop guidelines in support of using biosimilars in the oncology space. We discussed what steps are needed to improve physician confidence in using biosimilars.

Further episodes of Not So Different: a Podcast from The Center for Biosimilars

Further podcasts by Not So Different: a Podcast from The Center for Biosimilars

Website of Not So Different: a Podcast from The Center for Biosimilars